|
||||||||||||||||||||||
|
|
Phase II Randomized Study of Diphenhydramine Hydrochloride, Lorazepam, and Dexamethasone for Chemotherapy-Induced Nausea and Vomiting in Pediatric Patients With Newly Diagnosed Cancer
Alternate Title Diphenhydramine, Lorazepam, and Dexamethasone in Treating Nausea and Vomiting Caused By Chemotherapy in Young Patients With Newly Diagnosed Cancer
Objectives Primary
Secondary
Entry Criteria Disease Characteristics:
Prior/Concurrent Therapy:
Patient Characteristics:
Expected Enrollment 180A total of 180 patients will be accrued for this study. Outcomes Primary Outcome(s)Efficacy of diphenhydramine hydrochloride, lorazepam, & dexamethasone in preventing chemotx-induced nausea & vomiting (CINV) as measured by proportion of patients requiring rescue
medication for breakthrough nausea or emesis during chemotx Efficacy of diphenhydramine hydrochloride, lorazepam, and dexamethasone in preventing CINV for 3 days after completion of the first course of emetogenic chemotherapy Outline This is a randomized, prospective, double-blind, multicenter study. Patients are stratified according to the emetogenic potential of their chemotherapy regimen (high vs moderate). Patients are randomized to 1 of 2 treatment arms.
In both arms, treatment continues during the first course of chemotherapy. Patients may also receive rescue medication to control breakthrough nausea or emesis. Patients and their parents complete the Adapted Rhodes Index of Nausea, Vomiting, and Retching- Measured by Child/Parent questionnaire once before beginning chemotherapy, twice daily during chemotherapy, and for 3 days after completion of chemotherapy. Trial Lead Organizations H. Lee Moffitt Cancer Center CCOP Research Base
Note: The purpose of most clinical trials listed in this database is to test new cancer treatments, or new methods of diagnosing, screening, or preventing cancer. Because all potentially harmful side effects are not known before a trial is conducted, dose and schedule modifications may be required for participants if they develop side effects from the treatment or test. The therapy or test described in this clinical trial is intended for use by clinical oncologists in carefully structured settings, and may not prove to be more effective than standard treatment. A responsible investigator associated with this clinical trial should be consulted before using this protocol. |
NCI Home |
Images Version |
Contact Us |
Policies |
Accessibility |
Viewing Files |
FOIA |
Site Help |
Site Map
|
A Service of the National Cancer Institute |